Assertio Holdings Files Tender Offer Communication for $18/Share Cash Acquisition by Garda Therapeutics, Plus CVR

summarizeSummary

Assertio Holdings has filed the formal communication for the tender offer by Garda Therapeutics to acquire all outstanding shares for $18.00 per share in cash, along with a Contingent Value Right (CVR), following the definitive merger agreement announced earlier today.

check_boxKey Events

• Acquisition Terms Finalized

  Garda Therapeutics will acquire Assertio Holdings for $18.00 per share in cash, totaling $125.1 million, plus one Contingent Value Right (CVR) per share. This represents a 34.6% premium to the unaffected stock price on March 20, 2026.

• Board Recommends Tender Offer

  Assertio's Board of Directors has unanimously approved the merger agreement and recommends shareholders tender their shares in the offer.

• Strategic Divestiture with CVR Pass-Through

  The company previously divested its non-Rolvedon assets to Cosette Pharmaceuticals for $35 million upfront plus earnouts. The SPRIX-related earnouts from this divestiture will be passed through to Assertio shareholders via the CVR.

• Financing Secured

  The acquisition is supported by $17 million in equity financing from Joseph M. Limber and Brett K.E. Lund, and $87 million in debt financing from Colbeck Capital Management, LLC.

auto_awesomeAnalysis

This SC TO-C filing provides the formal tender offer communication to shareholders regarding the acquisition of Assertio Holdings by Garda Therapeutics. It follows the definitive merger agreement announced earlier today (2026-04-09 12:07). The offer of $18.00 per share in cash, plus a Contingent Value Right (CVR), represents a significant premium over the company's unaffected stock price. The CVR offers potential additional cash payments based on future milestones for the SPRIX product, which was part of a recent divestiture to Cosette Pharmaceuticals. This transaction provides a clear path to value realization for shareholders.